Astellas pays $285m for Audax cancer drug, and other deals
Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
GSK shares come under pressure from weaker vaccine sales
Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting to deliver.
Lilly's triple G overpowers Ozempic in diabetes trial
Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
AbbVie bids to join the BCMA crowd with etentamig
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
US MCT8 deficiency patients get 1st drug as Emcitate debuts
Egetis has launched the first-ever therapy for the ultra-rare disease MCT8 deficiency in the US, with a list price of $950,000 per year.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
31st Edition Strategic Project & Portfolio Management for Ph...
The Marcus Evans 31st Edition Strategic Project & Portfolio Management for Pharma conference, for European pharmaceutical PMO and portfolio leaders.
Women in AI - an evening of practical AI learning
Women in AI returns November 10 in London, UK. Join women from across healthcare for an evening of practical AI learning.
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event